Berg Insight expects 160 million home medical monitors in care programs by 2030

Worldwide, 92.7 million connected home medical monitoring devices were in use in 2025, and that figure counts only devices belonging to patients enrolled in mHealth care programmes. In new findings on the mHealth market released on October 22, Berg Insight forecasts that the total will rise at a compound annual growth rate of 11.5 percent to 159.7 million by 2030.

The Swedish research firm says market acceptance keeps growing across several key verticals. For anyone running a care program, the real question is where that growth lands. Berg's answer points to the categories with the most suppliers. IoT Business News described the challenge as shifting from simply collecting patient data to integrating it into clinical workflows and supporting timely medical interventions.

A count of prescribed devices only

Berg's figure leaves out consumer fitness trackers and personal wellness gadgets. Every unit in it belongs to a patient enrolled in an mHealth care program as part of a prescribed regimen. Manuel Nau, lead editor at IoT Business News, wrote that this makes the forecast a more focused measure of clinical IoT adoption than the wider wearables market. IoT Insider drew the same line in its coverage.

That narrow scope matters once you put Berg's number next to other forecasts. MarketsandMarkets projects the IoT medical devices market will grow from $65.08 billion in 2025 to $154.74 billion by 2030, a CAGR of 18.9 percent. That is a revenue estimate, and its end users include hospitals and nursing homes. By type, its largest share goes to stationary devices such as imaging systems and smart infusion pumps.

Grand View Research's 2022 report put the remote patient monitoring system market at $16.9 billion by 2030, growing 18.3 percent a year from 2022. It expected the home healthcare segment to grow at 22.0 percent. Both of those measure dollars across wider boundaries, while Berg counts devices in prescribed home use. Taken together, they suggest Berg's 11.5 percent sits at the clinically bounded, conservative end of the range. It doesn't contradict the others.

Compliance rules built sleep, diabetes builds the next wave

Sleep therapy is by far the most connected segment. ResMed dominates it, with Philips, BMC Medical and Löwenstein Medical Technology among the other suppliers. The number of remotely monitored sleep therapy patients has more than doubled since 2018. Berg puts that down mainly to compliance monitoring requirements introduced in the US and Europe.

Diabetes comes second, with 19.5 million connections at the end of 2025. Continuous glucose monitoring and connected insulin delivery from Abbott, Dexcom, Insulet, Tandem Diabetes Care and MiniMed are driving it. Implantable cardiac rhythm management is the oldest of the three. Medtronic, Abbott, Boston Scientific and BIOTRONIK started building connectivity into those devices more than two decades ago.

Payment policy also shows up in other forecasts. MarketsandMarkets cites supportive reimbursement, especially from the Centers for Medicare & Medicaid Services for remote monitoring, as one reason connected devices make financial sense for providers. That is part of how it explains North America holding the largest share of the IoT medical devices market in 2024, ahead of Europe and Asia Pacific.

Through 2030, Berg expects the fastest growth in diabetes management, remote ECG monitoring and medication compliance monitoring. Its other categories include telehealth, blood pressure monitoring and further connected care applications. Medication compliance fits the firm's wider argument that self-engagement apps and compliance monitoring tools help patients stick to prescribed treatment, which makes the regimen work better.

The supplier picture in those segments looks nothing like sleep. Berg's list of leading players there runs to 23 companies, which it describes as a mix of forward-thinking incumbents and innovative new entrants. AliveCor, iRhythm Technologies, Biotricity, Evondos, MedMinder and Hero Health appear alongside Medtronic, Roche, Dexcom, GE Healthcare and Withings. A program that grows through these categories will probably buy from more vendors, and each vendor brings its own device and data path.

The software layer decides the payoff

Berg frames the broader move as one from episodic care toward continuous monitoring and proactive intervention. Providers are adopting home-based models to improve outcomes, reduce avoidable hospitalisations and readmissions, manage costs and extend access to specialist care. The firm links that to ageing populations, rising healthcare costs and changing patient needs.

Berg calls mHealth software and services one of the fastest-developing parts of the value chain. Platforms collect vital signs and health metrics in real time from connected wearables and sensors. Service providers add data analytics, telehealth capabilities and patient engagement tools on top. Berg lists Huma Therapeutics, Doccla, Teladoc Health, CareSimple, Current Health, Amwell, Omron Healthcare's Luscii, Vivalink and Welldoc among the specialists. Its full list also includes Aptar Digital Health, Alira Health (Bepatient), Medisanté, MedM, S3 Connected Health, SHL Telemedicine, Tellihealth, TytoCare and Enovation (Legrand Care).

Vatsala Raina, an IoT analyst at Berg, said the market is moving past standalone connected devices toward integrated offerings that combine hardware, software and data analytics.

IoT Business News noted that device connectivity is still essential, but clinical value increasingly depends on combining data from different devices and fitting monitoring into existing care processes. The outlet added a third requirement, presenting meaningful insights to medical professionals. For device makers and IoT solution providers, it argued, that draws a line between selling connected hardware and taking part in a complete remote monitoring ecosystem, where interoperability, dependable data delivery and integration with healthcare software carry the weight.

Raina also pointed to artificial intelligence. In her view, AI and machine learning are speeding up the move to remote and home-based care. They spot early signs that a patient's condition is worsening, which supports timely interventions and lets healthcare providers handle patients more effectively away from traditional clinical settings. Any early-warning model would depend on the consolidated data these platforms exist to assemble, since it can only flag deterioration in readings that actually reach it.

Where the integration case is thinnest

The platform argument has limits. Sleep therapy, still the largest segment, centers on ResMed, and Berg ties its growth mainly to compliance requirements. There the connection does a specific job, documenting that patients use their therapy. With one dominant supplier, there are also fewer data paths to reconcile, so the multi-device integration problem is smaller.

A 2021 Medical Economics piece gave a cardiology example of how much a single signal can carry. Missing weight gain in a heart failure patient is catastrophic, it argued. Caught early, a physician can prescribe dietary changes or an extra dose of Lasix and an office visit. Missed, it can mean an emergency room visit or readmission, and congestive heart failure ranks among the five most expensive diagnosis-related groups. The same piece, citing published studies, said remote monitoring has cut emergency room visits by up to 92 percent and readmissions by up to 40 percent. Those are best-case ceilings, not typical results.

In that example, the payoff comes from one reading arriving in time, not from merging several streams. For a program built around one condition and one device, fast alerts and a clear escalation path could matter more than a multi-vendor platform.

Still, the forecast leans the other way. The three segments Berg expects to grow fastest are also the ones with the most suppliers. If the forecast holds, the 2030 installed base will lean further toward multi-vendor programs, and the platform question in the tip above becomes a standard part of buying devices.